Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06423352
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-28
First Post:
2024-05-15
Brief Title:
A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension
Sponsor:
Alnylam Pharmaceuticals
Organization:
Alnylam Pharmaceuticals
Study Overview
Official Title:
A Phase 12 Randomized Double-blind Placebo-Controlled Parallel-Group Study to Evaluate the Safety Tolerability Efficacy Pharmacodynamics and Pharmacokinetics of Zilebesiran in Japanese Patients With Mild to Moderate Hypertension
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety tolerability efficacy pharmacodynamics PD and pharmacokinetics PK of zilebesiran in Japanese patients with mild to moderate hypertension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None